- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Chemical and Structural Strategies to Selectively Target mTOR Kinase ; day:01 ; month:07 ; year:2021 ; extent:1
ChemMedChem ; (01.07.2021) (gesamt 1)
- Urheber
- DOI
-
10.1002/cmdc.202100332
- URN
-
urn:nbn:de:101:1-2021070115094292175736
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Borsari, Chiara
- De Pascale, Martina
- Wymann, Matthias P.
Ähnliche Objekte (12)
Chemical tools selectively target components of the PKA system
Chemical Proteomics Reveals the Target Landscape of Clinical Kinase Inhibitors.
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Off-target identification for a multitarget kinase inhibitor by Chemical Proteomics
EGFR and mTOR as therapeutic targets in glioblastoma
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
The role of the kinase mechanistic Target Of Rapamycin – mTOR – and the RNA-binding protein Pumilio2 in epileptogenesis
Novel strategies to selectively target vulnerabilities in T-prolymphocytic leukemia
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
CTX-CNF1 recombinant protein selectively targets glioma cells in vivo
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
Chemical tools selectively target components of the PKA system
Chemical Proteomics Reveals the Target Landscape of Clinical Kinase Inhibitors.
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Off-target identification for a multitarget kinase inhibitor by Chemical Proteomics
EGFR and mTOR as therapeutic targets in glioblastoma
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
The role of the kinase mechanistic Target Of Rapamycin – mTOR – and the RNA-binding protein Pumilio2 in epileptogenesis
Novel strategies to selectively target vulnerabilities in T-prolymphocytic leukemia
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
CTX-CNF1 recombinant protein selectively targets glioma cells in vivo
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
Chemical tools selectively target components of the PKA system
Chemical Proteomics Reveals the Target Landscape of Clinical Kinase Inhibitors.
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Off-target identification for a multitarget kinase inhibitor by Chemical Proteomics
EGFR and mTOR as therapeutic targets in glioblastoma
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
The role of the kinase mechanistic Target Of Rapamycin – mTOR – and the RNA-binding protein Pumilio2 in epileptogenesis
Novel strategies to selectively target vulnerabilities in T-prolymphocytic leukemia
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
CTX-CNF1 recombinant protein selectively targets glioma cells in vivo
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration